Roxithromycin is a semi-synthetic 14-membered-ring macrolide antibiotic, the in-vitro activity of roxithromycin is well documented and similar to that of other macrolide antibiotics. Roxithromycin is active against gram-positive and gram-negative cocci, gram-positive bacilli and some gram-negative bacilli, but has no significant effect on the predominant faecal flora[3]. Roxithromycin is very well tolerated with an overall incidence of adverse events of approximately 4%. Roxithromycin has proven clinical efficacy in upper and lower respiratory infections, skin and soft tissue infections, urogenital infections and orodental infections, and appears to be as effective as more established treatments including erythromycin, amoxicillin/clavulanic acid and cefaclor[4]. Macrolide antibiotics show antibacterial and anti-inflammatory efficacy in otitis media with effusion[5]. The increasing of RAGE (Receptor of Advanced glycation end products) in asthmatic rats are positively correlated with airway inflammation and airway remodeling. Roxithromycin may inhibit the development of asthma by reducing the expression of RAGE[6].
Italy
... 展开 >> Department of Medicine - DIMED, University of Padova, Italy
Not yet recruiting
Padova, Italy
Principal Investigator: Gian Paolo Rossi, MD 收起 <<
搜索
